Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSAR + DT +/- Pembrolizumab in BRAF-V600E+ Anaplastic Thyroid Cancer
NCT07886905Phase 2Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib, trametinib, pembrolizumab in anaplastic thyroid carcinoma (ATC), sponsored by Washington University School of Medicine. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
03
Conditions
anaplastic thyroid carcinoma (ATC)
Beyond the preview
Go deeper on NCT07886905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07886905.